NanoCube
Health
| Early Detect
| Early Intervene
| Thrive
There is an opportunity to revolutionise medicine with a new early detection, diagnosis and treatment approach. Only 3 out of 10 people survive more than a year after being diagnosed with pancreatic cancer, with a median survival period of 5-7 months (AIHW, 2023; Lundy, et al., 2021). Pancreatic cancer is often not detected until it has advanced because it usually doesn't exhibit symptoms in its early stages. There is also no early screening tool for pancreatic cancer, contributing to poor outcomes for many patients.
Leveraging Artificial Intelligence, Duobots™ is a groundbreaking nanorobotics device currently being developed by NanoCube Health to:
​
​
​
​Early detect pancreatic cancer forming at its earliest stage ​
​
​
​
Monitor treatment progress in real-time
​
​
​
​
​Deliver targeted treatment
Explore the 4-Part Startup Daily Series Featuring NanoCube Health
Sponsored by Dell Technologies
EP 1: CHANGING HEALTHCARE
EP 3: THE FOUNDERS TRIBE
EP 2: TRUE TECH INNOVATION
EP 4: TAKING THE GLOBAL STAGE
Watch the Dare to Hope documentary 
An insight into the life of former AFL Hawthorn player Paul Dear and his family, following his diagnosis of
terminal Stage 4 pancreatic cancer.
Available to stream exclusively on SBS on Demand and Kayo Sports
The technology under development is not yet commercially available. While we continue to advance product development, we strongly encourage people to know the signs of pancreatic cancer to promote earlier diagnosis.
Check out our careers page and follow us on LinkedIn to stay up-to-date with current employment opportunities at NanoCube Health.
Read about the latest news and issues relevant to nanotechnology, artificial intelligence and medical innovation.